Clinical Trial Detail

NCT ID NCT02259114
Title A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors OncoEthix
Indications

non-small cell lung carcinoma

pancreatic ductal adenocarcinoma

prostate cancer

carcinoma

Her2-receptor negative breast cancer

Therapies

Birabresib

Age Groups: adult

Additional content available in CKB BOOST